SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Biotechnology

Healthcare
$29.68 +2.49%

+$0.45 today

Market cap
$993.14M
Beta
-0.34
P/E (TTM)
-14.1
EPS (TTM)
-$1.32
52W Low $17.06High $32.44

Volume 0.10M

Average 0.09M

SGP Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

SpyGlass Pharma, Inc. Common StockNASDAQ: SGP

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities of $2.27M in Q1 FY2026

Q1 FY2026 other current liabilities was $2.27M.

Context

  • Other current liabilities amounted to 0.9% of total assets at the end of Q1 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.27M-61.4% QoQ
Last fiscal yearDec 2025
$5.89M— YoY
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
5.89M USD
Year-over-year change
—

Other Current Liabilities vs competitors

How SGP compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Other current liabilities amounts to 0.9% of total assets for SGP, versus a peer median of 7.3%.
SGP Competitors
Other Current Liabilities for SGP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BLCOBausch + Lomb CorporationJun 2026$1.42B USD+31.7%+25.7%10.3%
ALCAlcon Inc.Sep 2026$1.4B USD+12.2%-6.1%4.5%
GKOSGlaukos CorporationJun 2026$83.19M USD+3482.7%+28.8%9.0%
OCSOculis Holding AGMar 2026CHF 35.44M CHF+137.3%+32449.2%14.6%
STAASTAAR Surgical CompanyApr 2026$32.96M USD+26.0%+16.3%7.3%
OCULOcular Therapeutix, Inc.Mar 2026$28.45M USD——3.9%
RXSTRxSight, Inc.Mar 2026$18.75M USD—+14.2%6.2%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$8.89M USD+58.9%+20.6%3.1%
SGHTSight Sciences, Inc.Mar 2026$8.83M USD+72.3%-6.2%8.0%
SGPSpyGlass Pharma, Inc. Common StockMar 2026$2.27M USD——0.9%
Peer median (excluding SGP) —+58.9%+18.4%7.3%

Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.